Assessing Vir Biotechnology: Insights From 5 Financial Analysts
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
評估Vir生物技術：來自5位金融分析師的見解
Vir Biotechnology (NASDAQ:VIR) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
在過去的三個月中，有5位分析師對Vir Biotechnology（納斯達克股票代碼：VIR）進行了分析，揭示了從看漲到看跌的不同觀點。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
下表總結了他們最近的評估，說明了過去30天不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts have set 12-month price targets for Vir Biotechnology, revealing an average target of $64.8, a high estimate of $110.00, and a low estimate of $9.00. This current average has increased by 22.26% from the previous average price target of $53.00.
分析師已經爲Vir Biotechnology設定了12個月的目標股價，顯示平均目標股價爲64.8美元，最高估計爲110.00美元，最低估計爲9.00美元。目前的平均價格較之前的平均目標價53.00美元上漲了22.26％。
Deciphering Analyst Ratings: An In-Depth Analysis
解密分析師評級：深度分析
The standing of Vir Biotechnology among financial experts becomes clear with...
通過對近期分析師行爲的...
登入免費觀看全文
登入/註冊